

Economic Outlook for Health Systems & Perspective on Recent Events

Leadership Institute Roundtable

August 2022

CONFIDENTIAL AND PROPRIETARY

Any use of this material without specific permission of McKinsey & Company
is strictly prohibited



Disclaimer

These materials are being made available in response to the COVID-19 crisis. These materials are based on currently available information, which has not been independently verified, and do not contain all the information needed to determine a future course of action. Given the uncertainty surrounding the pandemic, these materials are not a guarantee of results, and future results could differ materially from any projections. These materials do not constitute legal, medical, policy or other regulated advice. These materials are provided “as is” solely for information purposes without any representation or warranty, and all liability is expressly disclaimed.

Analysis is focused on economic and business implications and does not address quality and access considerations.

Contents



Macroeconomic environment and responses
to accelerated inflation




Revenue diversification and key questions for
health systems



Capability-oriented collaboration for health
systems

The COVID-19 pandemic marked the end of a decade of relative calm in healthcare



Our current economic outlook reveals the degree of disruption

As of July 2022

Highest inflation levels since
1970s "Great Inflation"

8.6%

Consumer Price Index (CPI- U), percent
change from prior year, May 2022

Negative GDP growth and
decelerating consumer spending

-0.9%

Real GDP, annualized percent change from
previous, Q2 2022

Worst stock market
performance since 1970

21%

S&P 500 index, percent change
from January 1 to June 30, 2022

Lowest level of consumer
sentiment ever recorded

-42%

Year-over-year change,
June 2022

Rapidly worsening supply
chains

>5X

Increase in ocean shipping cost, coupled with
65% increase in trucking costs

Extreme volatility across
all segments

~2X

Increase in world uncertainty since
2010, corresponding with 30+ VIX


Consumer sentiment has fallen to all-time lows as inflation expectations persist

Last Updated July 07, 2022

— Current economic conditions (left scale) ■ Expected Inflation rate next year (right scale)

Consumer sentiment, current economic conditions
Index, 2005=100, through June 2022


Consumer expected inflation rate, next year
%, through June 2022



Wage gains for lower-paid workers are outpacing those of higher-paid workers

Wage growth tracker by wage level

12-month moving average of median wage growth for each category, hourly data (% growth)




— Bottom quartile — Top quartile

Given disproportionate wage growth, **businesses reliant on lower-paid workers may feel greater economic stress than others**


While real \$ compensation per hour has risen, **real \$ GDP per hour has slowed through the pandemic** (1.7% for Q1'15-Q4'19 vs. 1.1% for Q1'20 – Q1'22), further impacting performance

Labor force participation and employment to population ratios remain below pre-COVID levels

US civilian labor force participation rate, 16+
Percent, through June 2022



US civilian employment to population ratio, 16+
Percent, through June 2022




-0.6M

Fewer workers vs. December 2019. Labor force participation rate at lowest level since 1977

-0.7M

Fewer jobs vs. December 2019. Employment population ratio at lowest level since 2017

Healthcare workforce lags pre-pandemic levels, especially in nursing and post-acute care



1. May 2022 numbers preliminary, pending revision

Source: US Bureau of Labor Statistics (not seasonally adjusted)

Healthcare job openings relative to hires:

<1K

More openings than hires after the **Great Recession**

~500K


More openings than hires in the **late 2010s**

>1M

More openings than hires in the **Q2'22**

Price increases within hospital services lags overall inflation

Consumer price index (CPI) for all urban consumer (CPI-U), seasonally adjusted, 12-month % change, 2013-22




Historically, medical care services pricing has been tightly correlated with CPI, typically with a 6-month to 2-year lag

Payers' expectations of median Commercial rate escalators have risen from 2-3% to 4-5% given inflationary cycle

Providers surveyed are more pessimistic that they'll be able to compensate for cost increases

Question: Assuming your underlying costs increase at your organization, what is the likelihood you will be able to receive higher revenue to compensate?




Payers and providers surveyed believe operating margin will fall ~150 bps from '21 to '22, while services and technology players expect only ~20 bps decline

1. Defined as p.p. difference between respondents claiming they're likely to compensate costs vs. unlikely

History teaches us that resilient companies are much more likely to come out as winners – especially during crisis

TRS performance of ca. 1,000 global companies¹ during the 2007-08 Financial Crisis



Resilient companies achieve + ~ 100bps TRS driven by...

- Outperformance in earnings throughout the cycles and revenues in the recovery
- Faster and harder moves on productivity, preserving growth capacity
- Divestments in downturn phase, acquisitions when recovery started
- Operational and financial optionality

In practically all sectors, resilient companies demonstrate similar attributes


1.Total returns to shareholder; calculated as average of sub-sector medians performance of resilient and non-resilient. Includes 1,140 companies (excludes FIG & REITs)
2.Resilient companies defined as top geometric mean TRS quantile by sector.

What did resilient companies do differently?

Resilient Non-Resilient

Resilients moved faster, harder on productivity; preserved growth capacity

Operating costs¹, % of revenue change



Resilients focused on COGS reduction through operational effectiveness²




Note: Calculated as an average of different sub-sector medians for 'Resilients' and 'Non-resilients'. Excludes financial companies and REITs
1 Operating Costs = COGS + SG&A - D&A. Change in Op cost (as a % of revenue) between 2007 and 2009 for Downturn period and 2009 and 2011 for Recovery period; 2 Resilients' revenue grew at the same time period; COGS and SG&A not adjusted for D&A (D&A is the primary driver for the discrepancy between operating cost and sum of COGS + SG&A)

Resilient companies ("Resilients") defined as top TRS quantile by sector

Resilients divested more heading into the downturn and acquired more as the recovery started


Avg. of sector median divestment (or acquisition) %, As % of value of transactions



Note: This analysis excludes financial companies, and REITs. This analysis was conducted using fiscal years
1 Downturn is defined as all deals announced between 2007-2009; 2 Recovery is defined as all deal announced between 2010-2011

Resilients created optionality early in the recession – operational and financial

Change in Leverage ratio, (Debt¹/Capital²)



Note: Calculated as an average of different sub-sector medians for 'Resilients' and 'Non-resilients'. Excludes financial companies and REITs
1 Total Debt (book value) = Short Term Borrowings + Current Portion of Long Term Debt + Current Portion of Capital Lease + Long Term Debt + Long Term Capital Lease + Finance Division Debt Current + Finance Division Debt Non Current; 2 Capital = Total Common Equity + Total Preferred Equity + Minority Interest + Total Debt.; 3 Downturn is defined as 2007 and 2009; Recovery is defined as 2009-2011

Contents



Macroeconomic environment and responses
to accelerated inflation



Revenue diversification and key questions for
health systems




Capability-oriented collaboration for health
systems

Legacy players in S&P 500 have held their equity value while many entrants have seen declines

Stock Price of Select Companies & Indexes since July 2021,
Relative to July 2021 (or post-July 2021 IPO price)

Price change since July '21, Percentage (%)



1. 5-week rolling average median of select public market players; 2. Average July 25th, 2022, stock price for select public market players relative to July 1st, 2021, stock price

Private companies are also seen declines, and IPO activity has slowed considerably

Industry news



Valuation fell to **~\$6B from ~\$15B** in June '22 in response to inflation, rates, and recession expectation




Lowered private valuation **~40% to \$24B** in late March '22



Announced **~30% valuation decline** in July '22 amidst impact to FinTech

Across industries, **private companies are trading at >20% discount** compared to Q4 2021, while companies that went public in 2021 **are >40% lower than their IPO**¹

U.S. IPO activity by year,
Number of IPO transactions (#)²




Across 1H 2022, **only 43 companies announced IPOs** on U.S. exchanges, the weakest six-months since 2016, and a **>80% drop YOY**

Investments in U.S. tech start-ups fell 23% over the last three months, to \$62B, the steepest fall since 2019


1. Ernst & Young and Forge Global
2. Renaissance Capital (as of July 19th, 2022)

Landscape of healthcare profit pools through 2025




1. Because of rounding, segment estimates may not sum to vertical totals
2. FBS = fixed-benefit and supplemental; PBM / PBA = pharmacy benefit administrator / pharmacy benefit manager

Most provider segments are projected for growth, led by specialist physicians and home health




Health systems surveyed ranked telehealth, VBC services, and ASCs as the most attractive investment themes



Note: Includes only those themes with at least 10 responses


Physicians' view virtual health as decelerating



QCOVID_TRENDSRANK: Coming out of the COVID-19 crisis, what trends do you think will have the most lasting impact on healthcare over the next 3-5 years? (Rank 1-3)
1: Excludes those who don't know


Payers are investing behind consumer themes as key trend, with particular focus on MA and highlighting superior results to traditional Medicare in earnings calls

A minority of physicians report participating in risk-based models, and few who do claim a “very good understanding”



QVB6: Do you currently participate in any risk-based alternative payment models with health insurance companies?
QVB2D: For the risk-based payment programs that you are participating in, do you know what types of operational metrics need to be changed to achieve your goals?

Increasing focus is being placed on select specialties



		Relative importance of levers		
	Potential theses	Ancillary expansion	Risk enablement	Site of care shifts
Women’s health	Consolidation enables expansion into high-margin ancillary services for OB/GYN and entry into adjacent specialties	●	◐	◐
GI	Increase procedure facility fees from ASC ownership, insourcing service lines, and increasing productivity by employing staff physician extenders	●	◐	◐
Dermatology	Value capture from ancillary service expansion (e.g., Mohs, pathology), use of extenders, and savings in admin cost	●	◐	◐
Urology	Value capture from insourcing procedures, ASC ownership, and improving efficiency	●	◐	◐
Nephrology	Provide analytics and care management resources for late-stage patients, enable contracting with MA payors and in full risk models	◐	●	◐
Ortho	Ortho ASCs expansion captures value from episode-based payments and technical revenues; Provision of ancillary services drives further upside	◐	◐	◐
Cardiology	Move catheterizations into ASCs; additional value from low-cost site of care (for VBC), staffing extenders, and adjacent ancillaries	◐	◐	◐
Oncology	Create integrated ambulatory ecosystem and pharmacy; drive penetration of growing interest in value-based care	◐	◐	◐

Despite enthusiasm from providers, **ASCs have grown at only ~1% p.a. over the past five years**

ASC landscape is still fragmented, with the largest five companies operating <30% of centers

SOURCE: Irving Levin, CMS

Contents



Macroeconomic environment and responses
to accelerated inflation




Revenue diversification and key questions for
health systems




Capability-oriented collaboration for health
systems

While approaches to diversification vary, most health systems intend to partner with others

Approach to diversification



Partnership intention



Health systems have multiple options beyond traditional M&A


Mergers & acquisitions

Partnerships

Joint ventures

Alliances

Large deal M&A



Full combination
of two entities,
target is >30%
acquirer market cap

All degrees
of operational
integration possible


Programmatic & “tuck-in” M&A



Full acquisition
of single asset/
series of smaller,
related assets

All degrees
of operational
integration possible


Full business joint venture



Partner
contributions
placed into new
JV entity

Operations led
by separate
management team


Partial business joint venture



Select resources contributed into a new JV entity

Vital other
resources
remain in parent
companies


“Consortium play” joint venture



Parents contribute capital to new entity to jointly purchase asset


All previously
existing resources
remain in parents

Strategic alliance with equity holding



Partnership is substantiated with noncontrolling (cross) shareholding


Contractual alliance



Resources are made available to the partner, but remain inside the parent



Examples of scaling healthcare alliances




1. Echo Health has since added other systems, including Blue Cross Blue Shield of Tennessee and the USAble Corporation

Successful collaboration models tend to follow a few conditions

- ✓ Is there a **substantial enough opportunity** to merit investing time and resources? Would the partnership be **competitively differentiated**?
- ✓ Is there **incremental value from scaling inputs via collaboration** beyond what could be achieved standalone?
- ✓ Is the capability one that **several (10+) health systems can participate in**, including players in overlapping geographies?
- ✓ Does participating in the partnership enable individual systems to improve performance and **avert a high upfront cost and/or scarcity of talent**?
- ✓ Does it **minimally impact day-to-day patient care and/or essential workflows**?

Multiple avenues for expanded collaborations



Are there additional areas that are top-of-mind for consideration?


Key messages



Everyone is grappling with challenging conditions; not-for-profit systems should weigh whether and when to pull levers that for-profits will



Many health systems have yet to pivot capital and focus to high growth areas, with innovation often being driven outside of the non-profit ecosystem



Collaboration models should allow health systems to build capabilities and shape the future direction of healthcare

McKinsey
& Company

Questions?

Neil Rao

Senior Partner | Seattle
Neil_Rao@mckinsey.com

